Analgesic Efficacy of Maxigesic in Breast Cancer Surgery

The present study aims to find a perioperative analgesic method that provides sufficient analgesia while reducing immune compromise in cancer surgery. This study is to investigate the analgesic effect and safety of Maxigesic inj. (a combination of acetaminophen 1000 mg and ibuprofen 300 mg), which is added to opioid-based IV-PCA in patients undergoing breast cancer surgery.

Trial Details

NCT ID

NCT06174363

Phase

Sponsor

Yonsei University

Status

RECRUITING

Cancer Type

Breast Cancer

Interventions

Maxigesic
0.9% saline solution

Locations (sample)

Seoul, South Korea|37.566,126.9784

Key Eligibility Criteria

Patient aged 20 to 70 years with ASA classification 1 to 3 undergoing breast cancer surgery (cancer resection or reconstruction)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →